相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biochemical basis for the functional switch that regulates hepatocyte growth factor receptor tyrosine kinase activation
Payal R. Sheth et al.
BIOCHEMISTRY (2008)
A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway
Zohar Tiran et al.
CLINICAL CANCER RESEARCH (2008)
Molecular imaging of hypoxia
Kenneth A. Krohn et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts
H. Toni Jun et al.
CLINICAL CANCER RESEARCH (2007)
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer
Roy S. Herbst et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase
Christine M. Stellrecht et al.
CANCER RESEARCH (2007)
Hepatocyte growth factor and c-Met expression in pericytes: implications for atherosclerotic plaque development
Y. Liu et al.
JOURNAL OF PATHOLOGY (2007)
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts
Neelu Puri et al.
CANCER RESEARCH (2007)
c-Met is a potentially new therapeutic target for treatment of human melanoma
Neelu Puri et al.
CLINICAL CANCER RESEARCH (2007)
Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma
Vicki L. Goodman et al.
CLINICAL CANCER RESEARCH (2007)
Food and drug administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma
Edwin P. Rock et al.
ONCOLOGIST (2007)
FDA drug approval summary: Bevacizumab (Avastin (R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer
Martin H. Cohen et al.
ONCOLOGIST (2007)
A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo
Tobias Martens et al.
CLINICAL CANCER RESEARCH (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions
Alessandro Morabito et al.
ONCOLOGIST (2006)
Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels
VJ Yao et al.
CANCER RESEARCH (2006)
Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts
KJ Kim et al.
CLINICAL CANCER RESEARCH (2006)
Angiogenesis as a therapeutic target
N Ferrara et al.
NATURE (2005)
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
R Abounader et al.
NEURO-ONCOLOGY (2005)
Hepatocyte growth factor promotes lymphatic vessel formation and function
K Kajiya et al.
EMBO JOURNAL (2005)
Mechanisms and significance of bifunctional NK4 in cancer treatment
K Matsumoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation
AST Wong et al.
EXPERIMENTAL CELL RESEARCH (2004)
A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation
P Peschard et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants
S Berthou et al.
ONCOGENE (2004)
Targeting the tumor and its microenvironment by a dual-function decoy Met receptor
P Michieli et al.
CANCER CELL (2004)
The Sema domain of Met is necessary for receptor dimerization and activation
M Kong-Beltran et al.
CANCER CELL (2004)
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts
T Inai et al.
AMERICAN JOURNAL OF PATHOLOGY (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cells
ME Gerritsen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2003)
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells
LX Song et al.
ONCOGENE (2003)
HGF receptor up-regulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro
SL Ding et al.
BLOOD (2003)
Autocrine activation of the hepatocyte growth factor receptor/Met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion
J Vadnais et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Activated c-Met signals through PI3K with dramatic effects on cytoskeletal functions in small cell lung cancer
G Maulik et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2002)
Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine
N Horiguchi et al.
ONCOGENE (2002)
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition
G Maulik et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
分享论文
